Previous 10 | Next 10 |
2023-05-10 10:51:53 ET Shares of CTI BioPharma (NASDAQ: CTIC) were up more than 80% early Wednesday after the company announced it was getting bought out for $1.7 billion by Swedish Orphan Biovitrum AB (OTC: BIOVF) , also known as SOBI. CTI BioPharma specializes in targe...
2023-05-10 10:00:34 ET Gainers: CTI BioPharma ( CTIC ) +85% . Cano Health ( CANO ) +29% . TScan Therapeutics ( TCRX ) +24% . RxSight ( RXST ) +11% . Guardant Health ( GH ) +14% . Losers: Babylon Holdings ( BBLN ) -71...
2023-05-10 03:32:11 ET Swedish Orphan Biovitrum AB or SOBI, a global healthcare leader in hematology, immunology and specialty care, will acquire CTI BioPharma ( NASDAQ: CTIC ) for $9.10 per share in an all-cash transaction. This represents an implied equity value of ~$1.7B....
Sobi to Acquire CTI BioPharma PR Newswire Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial ...
CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023 PR Newswire SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the develop...
CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire – Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion –...
2023-04-21 07:46:10 ET Summary CTI BioPharma's sole product crushed rival drug Inrebic in fourth-quarter domestic sales. However, Wall Street expected too much revenue, leading shares to drop 10% following the Q4 call. Favorable placement among health insurers will lead to con...
CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023 PR Newswire SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization...
2023-03-31 08:21:20 ET Summary CTI BioPharma reported Q4 2022 earnings with VONJO sales of $21.1 million, which missed consensus estimates. However, the slower quarter was attributed to seasonality in the oncology industry. Although sales growth slowed compared to the previous qua...
2023-03-06 17:35:33 ET Major earnings expected after the bell on Tuesday include: CrowdStrike Holdings ( CRWD ) Stitch Fix ( SFIX ) Cherry Hill Mortgage Investment Corporation ( CHMI ) Yext ( YEXT ) W&T Offshore ( WTI ) For further details...
News, Short Squeeze, Breakout and More Instantly...
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders PR Newswire SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization ...
Shares of CTI BioPharma Corp. (NASDAQ: CTIC) traded at a new 52-week high today and are currently trading at $8.99. So far today, approximately 1.79M shares have been exchanged, as compared to an average 30-day volume of 10.16M shares. CTI BioPharma Corp., a biopharmaceutical company, focuses...
NEW YORK, NY / ACCESSWIRE / May 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ: FRG)'s ...